CRISPRi-mediated validation of candidate Mycobacterium abscessus drug targets during host infection
Preprint
Abstract
Mycobacterium abscessus ( Mab ) is a multidrug-resistant nontuberculous mycobacterium that causes debilitating TB-like pulmonary infections for which effective treatment options are lacking. Poor in vivo drug efficacy may stem from altered vulnerability of drug targets driven by host-specific environmental conditions. To enable validation and prioritization of candidate drug targets in vivo , we exploited CRISPRi (CRi) gene silencing in multiple mouse infection models. Inducible silencing of ftsZ Mab , a previously validated target, and three predicted targets ( leuS Mab , folP Mab , fusA Mab ) confirmed their essentiality in vitro . We then assessed the in vivo vulnerability of these targets in both immunocompetent C57BL/6N and immunodeficient NSG mice by assessing the impact of CRi silencing on pulmonary mycobacterial burden. In NSG mice, silencing of all four genes led to comparable decreases in Mab burden. However, in C57BL/6N mice, the degree of Mab clearance varied among targets, suggesting that immune pressure may influence the outcome of CRi-mediated gene silencing. Notably, repression of fusA Mab yielded a larger decline in mycobacterial burden in C57BL/6N mice despite a lower level of gene silencing in vitro , consistent with enhanced vulnerability of this target. Overall, this study demonstrated that ftsZ Mab , leuS Mab , folP Mab , and fusA Mab are essential for Mab growth in vitro and, for the first time, validated their vulnerability to inhibition by CRi during infection. These data also identified potential context-dependent target vulnerabilities, which could inform the prioritization of bacterial drug targets and accelerate the development of effective therapeutics for Mab infections.Keywords
This publication has 55 references indexed in Scilit:
- The evaluation of Phenylalanine-tRNA ligase beta unit (PheT), as a potential target in Mycobacterium abscessusTuberculosis, 2025
- Genome-scale CRISPRi screening: A powerful tool in engineering microbiologyEngineering Microbiology, 2023
- CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRiMolecular Therapy, 2023
- Implementation of a mycobacterial CRISPRi platform in Mycobacterium abscessus and demonstration of the essentiality of ftsZMabTuberculosis, 2022
- Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosisCell, 2021
- Engineered Regulatory Systems Modulate Gene Expression of Human Commensals in the GutCell, 2017
- Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene ExpressionCell, 2013
- Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteriaDrug Resistance Updates, 2012
- Mycobacterium tuberculosis Invasion of Macrophages: Linking Bacterial Gene Expression to Environmental CuesCell Host & Microbe, 2007
- Diagnosis of nontuberculous mycobacterial infectionsClinics In Laboratory Medicine, 2002